HIV Neurocognitive Disorders Innovations|OMICS International|Journal Of AIDS And Clinical Research

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

HIV Neurocognitive Disorders Innovations

Human Immunodeficiency virus (HIV) associated neurocognitive disorders have been reported in up to 50% of patients on highly active antiretroviral therapy (HAART). Even though screening for neurocognitive impairment (NCI) is not routinely done or recommended by current treatment guidelines, NCI is associated with HAART noncompliance and functional impairment, and is currently being linked to cerebrospinal fluid escape (positive CSF HIV RNA PCR in the setting of undetectable serum HIV RNA PCR). The Montreal cognitive assessment (MoCA) has been validated and widely used in several countries and languages in non-HIV infected populations to screen for cognitive impairment. Innovations are new idea, device or process. Innovations are the application of better solutions that meet new requirements, in articulated needs or existing market needs. It is proficient through more effective products, processes, services, technologies, or new ideas that are readily available to markets, governments and society. Innovations are something original and novel, as a significant, new that “breaks into” the market or society.
  • Share this page
  • Facebook
  • Twitter
  • LinkedIn
  • Google+
  • Pinterest
  • Blogger

Last date updated on January, 2021